BioSpace News Archive

Brii Biosciences Limited provided updates on its diverse pipeline of infectious disease and central nervous system disease candidates and announced a pivotal leadership transition that will further advance its strategic priorities.

Brii Biosciences Limited announced that it has entered into license agreements with VBI Vaccines, Inc., expanding the companies’ collaboration in the hepatitis B virus field.

Ascentage Pharma announced that the Center for Drug Evaluation of the China National Medical Products Administration has approved a registrational pivotal Phase III study of olverembatinib, Ascentage Pharma’s lead drug candidate, in combination with chemotherapy comparing imatinib in combination with chemotherapy for treatment of patients with naïve Philadelphia chromosome-positive acute lymphoblastic leukemia.

Clarius Mobile Health, a leading provider of high-definition handheld ultrasound systems, and Usono, a developer of innovative ultrasound accessories, joined forces today at the ECSS Paris 2023 congress to introduce a ground-breaking wireless and wearable ultrasound imaging solution for researchers studying the anatomy of people while they move.

Biosion, Inc. (“Biosion”), a global, clinical-stage biotechnology company, today announced the appointment of Furqan Ahmed, PharmD., as the Vice President and Head of Business Development.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its wholly owned subsidiaries have received, in aggregate, $1.2 million related to research tax incentives from the Austrian and Australian governments for research expenditures performed in 2021 and 2022.

Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock.

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 60,250 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 18,000 shares of Arcutis’ common stock to seven newly hired employees.

Merus N.V. (Nasdaq: MRUS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for zenocutuzumab (Zeno) for the treatment of patients with advanced unresectable or metastatic NRG1 fusion (NRG1+) non-small cell lung cancer (NSCLC), following progression with prior systemic therapy.

Terns Pharmaceuticals, Inc. announced that it has granted as of July 1, 2023 equity inducement awards to five new employees under the terms of the 2022 Employment Inducement Award Plan.